Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last341 to 360 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI) | 77 of 16,263 101 of 8,152 | -0.8 points -1.0 to -0.5 | 24,415 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | 44 of 16,263 63 of 8,152 | -0.5 points -0.7 to -0.3 | 24,415 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Predefined Clinically Relevant Disease Associated With RT-PCR-Confirmed RSV-Mediated ARI Over the Whole Study | 4 of 16,263 11 of 8,152 | -0.1 points -0.2 to -0.0 | 24,415 | NCT04908683 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
| Standard CPR vs Continuous Chest Compressions: Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge | 1,072 of 11,022 1,127 of 12,603 | 0.8 points 0.0 to 1.5 | 23,625 | NCT01372748 Continuous Chest Compressions vs AHA Standard CPR of 30:2 |
| Synflorix Group vs Control Group: deaths from any cause | 19 of 11,798 26 of 11,799 | -0.1 points -0.2 to 0.1 | 23,597 | NCT00466947 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine |
| Synflorix Group vs Control Group: serious adverse events | 2,534 of 11,798 2,668 of 11,799 | -1.1 points -2.2 to -0.1 | 23,597 | NCT00466947 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine |
| Fluarix Quadrivalent vs mRNA-1010: deaths from any cause | 44 of 11,250 45 of 11,252 | -0.0 points -0.2 to 0.2 | 22,502 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Hypotension Decision Support vs Usual Care Group: deaths from any cause | 158 of 4,972 534 of 17,463 | 0.1 points -0.4 to 0.7 | 22,435 | NCT02726620 Decision Support for Intraoperative Low Blood Pressure |
| Hypotension Decision Support vs Usual Care Group: serious adverse events | 541 of 4,972 1,811 of 17,463 | 0.5 points -0.4 to 1.5 | 22,435 | NCT02726620 Decision Support for Intraoperative Low Blood Pressure |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With Unsolicited Adverse Events (AEs) | 1,495 of 11,200 1,351 of 11,210 | 1.3 points 0.4 to 2.2 | 22,410 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: serious adverse events | 495 of 11,200 518 of 11,210 | -0.2 points -0.7 to 0.3 | 22,410 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Zostavax™ vs Placebo: Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period | 69 of 11,094 61 of 11,116 | 0.1 points -0.1 to 0.3 | 22,210 | NCT00534248 Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) |
| Zostavax™ vs Placebo: serious adverse events | 243 of 11,094 233 of 11,116 | 0.1 points -0.3 to 0.5 | 22,210 | NCT00534248 Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine | 142 of 11,026 140 of 11,055 | 0.0 points -0.3 to 0.3 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine | 85 of 11,026 75 of 11,055 | 0.1 points -0.1 to 0.3 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine | 3 of 11,026 3 of 11,055 | 0.0 points -0.1 to 0.1 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains | 70 of 11,026 70 of 11,055 | 0.0 points -0.2 to 0.2 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine | 91 of 11,026 81 of 11,055 | 0.1 points -0.1 to 0.3 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine | 45 of 11,026 40 of 11,055 | 0.0 points -0.1 to 0.2 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
| Fluarix Quadrivalent vs mRNA-1010: Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains | 44 of 11,026 38 of 11,055 | 0.1 points -0.1 to 0.2 | 22,081 | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=18
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04908683-44a47b1c",
"title": "Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI)",
"summary": "77 of 16263 against 101 of 8152; risk difference -0.8 points, 95% interval -1.0 to -0.5; NCT04908683, A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
"record": "/library/comparisons/NCT04908683-44a47b1c",
"nct_id": "NCT04908683",
"kind": "outcome",
"participants": 24415,
"risk_difference": {
"value": -0.007654923845327753,
"lower": -0.010459997404381596,
"upper": -0.005175111830331038
},
"group_1": "77 of 16,263",
"group_2": "101 of 8,152",
"difference": "-0.8 points",
"interval": "-1.0 to -0.5",
"trial_title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older"
},
{
"id": "NCT04908683-8d04ff99",
"title": "Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)",
"summary": "44 of 16263 against 63 of 8152; risk difference -0.5 points, 95% interval -0.7 to -0.3; NCT04908683, A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
"record": "/library/comparisons/NCT04908683-8d04ff99",
"nct_id": "NCT04908683",
"kind": "outcome",
"participants": 24415,
"risk_difference": {
"value": -0.005022636982133173,
"lower": -0.007277082506567847,
"upper": -0.0031027824186859367
},
"group_1": "44 of 16,263",
"group_2": "63 of 8,152",
"difference": "-0.5 points",
"interval": "-0.7 to -0.3",
"trial_title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=19",
"request_id": "STgdyVCA2NOO2GfU"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant